Glenmark Pharmaceuticals announced that its Brazilian subsidiary, Glenmark Farmaceutica Ltda has entered into an exclusive partnership agreement with Novartis Biosciences S.A, a subsidiary of Novartis AG, for three breathing products indicated toward remedy of the signs of chronic obstructive pulmonary disorder (COPD) in Brazil. This agreement might be effective from July 01, 2019 onwards.
The merchandise concerned within the agreement are Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (mixture of Indacaterol and Glycopyrronium), which are indicated for alleviation of signs and symptoms in adults with COPD.
Bazaarinformation team has many years of experience, covering the physical and future commodities markets with prominent commodity & equity trading advising which shines further with extensive network to get research from ground levels to generate proper reporting and movements. We are able to get evens out of odds in volatile markets and stockings. ...
